secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001104659-23-114520
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex announces positive Phase 2 CSU data for barzolvolimab; $12.5M milestone triggered
--------------------------------------------------------------------------------

- Barzolvolimab met primary endpoint: LS mean UAS7 change from baseline to week 12 was -23.87 (300mg q8w) vs -10.47 placebo (p<0.0001).
- Complete control (UAS7=0) at week 12: 37.5% (300mg q8w), 51.1% (150mg q4w), 22.9% (75mg q4w) vs 6.4% placebo.
- Positive Phase 2 data triggers $12.5M milestone payment under settlement agreement with SRS, to be paid in cash.
- Phase 1B data in prurigo nodularis showed meaningful itch reduction and clear/almost clear skin with single 3.0 mg/kg dose.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465923114520/0001104659-23-114520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465923114520/tm2329928d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer